2.5. HSP90 Modulation Influences Cellular Response of HER2-Driven Breast Cancer Cells to the Combination of Trastuzumab, Pertuzumab, and Tamoxifen and Trastuzumab Emtansine (TDM-1). Here, ERBB2 is linked to breast carcinoma.